Connor, Clark & Lunn Investment Management (CC&L)
BCLI

Connor, Clark & Lunn Investment Management (CC&L)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-791
Closed -$24.4K – 1366
2023
Q2 		$24.4K Buy
+791
New +$32.8K ﹤0.01% 1282

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BCLI Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 791 shares — an estimated $24.4K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BCLI in Q2 2023 and held it in 1 quarter. The position peaked at $24.4K in Q2 2023. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 791 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $24.4K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2023 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s BRAINSTORM CELL THERAPUTC position peaked at $24.4K in Q2 2023.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.